Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Transitional Cell 5Acrocephalosyndactylia 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma 1Breast Neoplasms 1

Interventions

pemigatinib 2pembrolizumab 1infigratinib 1erdafitinib 1derazantinib 1atezolizumab 1Rogaratinib 1Gemcitabine 1Drug Combinations 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Acrocephalosyndactylia × pemigatinib × Genitourinary × Clear all
NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Incyte Corporation

Phase 2 Terminated
7 enrolled 10 charts
Genitourinary

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT02872714 2025-08-14

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Incyte Corporation

Phase 2 Completed
263 enrolled 20 charts
Genitourinary

Acrocephalosyndactylia, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡